Consistently, immunohistochemical (IHC) staining of different GI tumors and NAT tissues with pan‐lactylation antibodies revealed a significantly higher signal intensity in cancer tissues (Figure 1F; Figure S3A‐C, Supporting Information), suggesting that the GI proteome is widely targeted by Kla modifications in cancer tissues. The gene discussed is BRD2; the disease is digestive system neoplasm.